ARS Pharmaceuticals, Inc. (SPRY)

6.005 +0.12 (+1.95%) USD  |  NASDAQ  |  Aug 31, 16:00
6.005 0.00 (0.00%) After-Hours: 20:00
More

ARS Pharmaceuticals Cash from Operations (Annual) : -170.87M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for SPRY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2018. Start Trial.
Date Value
December 31, 2025 -170.87M
December 31, 2024 13.55M
December 31, 2023 -59.27M
December 31, 2022 -40.08M
Date Value
December 31, 2021 -17.56M
December 31, 2020 -31.20M
December 31, 2019 -18.90M
December 31, 2018 -16.88M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Passage Bio, Inc. -31.51M
Vertex Pharmaceuticals, Inc. 3.631B
Capricor Therapeutics, Inc. -69.81M
Kyntra Bio, Inc. -4.82M
Zentalis Pharmaceuticals, Inc. -125.25M